SLS at an Inflection: Hold Existing Positions While Phase-3 Uncertainty Plays Out
SELLAS Life Sciences (SLS) is a small-cap clinical-stage biotech that has drawn attention after encouraging early-stage immunotherapy and CDK9 data. The stock ($4.70) sits between its 52-week low ($1.29) and high ($6.14), with an elevated short-interest profile and heavy trading. Given an upcoming clinical inflection for its AML program and stretch…